The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly sell their drugs to certain patients ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Photo: Scott Olson () Getting access to popular weight loss drugs will be simpler and cheaper for some. Health insurer Cigna ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...